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ABSTRACT
Epidemiologic studies have demonstrated an association of elevated plasma homocysteine levels with greater bone resorption and
fracture risk. Vitamins B12, B6, and folic acid are cofactors in homocysteine metabolism, and supplementation with B vitamins is
effective in lowering homocysteine levels in humans. However, randomized trials of supplemental B vitamins for reduction of
fracture risk have been limited. Therefore, we performed an ancillary study to theWomen’s Antioxidant and Folic Acid Cardiovascular
Study (WAFACS), a large randomized trial of womenwith preexisting cardiovascular disease or three ormore coronary risk factors, to
test whether a daily B vitamin intervention including folic acid (2.5mg/day), vitamin B6 (50mg/day), and vitamin B12 (1mg/day)
reduces nonspine fracture risk over 7.3 years of treatment and follow-up. Among 4810 women, we conﬁrmed 349 nonspine fracture
cases by centralized review of medical records. In a substudy of 300 women (150 in treatment group and 150 controls) with paired
plasma samples at randomization and follow-up (7.3 years later), we measured two bone turnover markers, including C-terminal
cross-linking telopeptide of type I collagen (CTX) and intact type I procollagen N-propeptide (P1NP). In Cox proportional hazards
models based on intention-to-treat, we found no signiﬁcant effects of B vitamin supplementation on nonspine fracture risk (relative
hazard¼ 1.08; 95% conﬁdence interval, 0.88 to 1.34). In a nested case-cohort analysis, there were no signiﬁcant effects of B vitamins
on fracture risk among women with elevated plasma homocysteine levels, or low levels of vitamins B12 or B6, or folate at baseline.
Furthermore, treatment with B vitamins had no effect on change in markers of bone turnover. We found no evidence that daily
supplementation with B vitamins reduces fracture risk or rates of bone metabolism in middle-aged and older women at high risk of
cardiovascular disease. © 2017 American Society for Bone and Mineral Research.
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Introduction
Osteoporotic fractures are a leading cause of disability inolder adults, and a major contributor to medical care costs
around the world.(1) Therefore, the identiﬁcation of modiﬁable
risk factors for osteoporosis is of high importance to improve
public health. It is especially important to identify inexpensive
and effective treatments for osteoporosis that are available even
to those with limited resources.
Dietary supplementation with the nutrients folic acid,
vitamin B12, and vitamin B6 has been proposed as one such
candidate treatment. These three vitamins are cofactors in
homocysteine metabolism, and studies have shown that as
many as two-thirds of cases of elevated homocysteine are
associated with low plasma folate or vitamin B12.
(2)
Randomized trials in adults have demonstrated that treat-
ment with folic acid and B vitamins can signiﬁcantly lower
plasma homocysteine levels,(3,4) although the extent of
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homocysteine-lowering may depend on the prevalence of
poor vitamin intake.(5)
Results from several epidemiologic studies have demon-
strated an association between elevated plasma homocysteine
levels and increased risk of osteoporotic fractures,(6–8) including
hip fractures.(9) Furthermore, high homocysteine levels have
been associated with increased bone resorption.(10–12) Addi-
tionally, a recent study based on data and samples from the
National Health and Nutrition Examination Survey (NHANES)
study demonstrated that elevated serum homocysteine and
lower folate levels (but not B12 levels) correlated cross-
sectionally with lower lumbar and total body bone mineral
density (BMD).(13)
Despite relatively strong epidemiologic evidence, results of
prior clinical trials to determine if administration of B vitamins
can reduce fracture risk have been inconclusive.(14–17) For
example, in the B-Vitamins for the Prevention of Osteoporotic
Fractures (B-PROOF) study, over 2900 older adults with elevated
homocysteine levels were randomized to receive daily B12 and
folic acid supplementation or placebo for a period of 2 years. No
signiﬁcant differences in fracture incidence were observed
overall, though there was a suggestion of protective effect
among compliant individuals over 80 years old.(14) Two other
studies, conducted among individuals at high risk of cardiovas-
cular disease(15) or recent stroke,(17) found no signiﬁcant
association of homocysteine-lowering therapy and fracture
risk. Only one study among older Japanese persons with
ischemic stroke reported a signiﬁcant reduction of fracture risk
in those taking daily folic acid and vitamin B12 compared to
placebo.(16) However, the study, by Sato and colleagues,(16) was
recently retracted, invalidating those positive ﬁndings.(18)
Similarly, results of most previous trials testing the effects of B
vitamins on markers of bone turnover(19–22) have also failed to
demonstrate signiﬁcant effects. However, these studies have
also suffered from small sample size and most were relatively
short-term trials of 3 to 6 months.(20–22)
To test the hypothesis that treatment with a regimen of folic
acid, vitamin B6, and vitamin B12 would reduce the risk of
incident fractures and inﬂuence levels of bone turnover markers
pretreatment and posttreatment in women, we performed an
ancillary study to the Women’s Antioxidant and Folic Acid
Cardiovascular Study (WAFACS), a large, double-blind, random-
ized placebo-controlled trial originally designed to test the
effects of antioxidants and B vitamins on cardiovascular disease
outcomes in women at high cardiovascular disease (CVD) risk.
We further hypothesized that women with elevated homocys-
teine levels, or low serum levels of folic acid and vitamins B6 or
B12 would experience the greatest beneﬁts of treatment.
Subjects and Methods
Study population
The WAFACS was a randomized, double-blind, placebo-
controlled trial, originally designed to test the effects of
antioxidant vitamins (vitamin C, vitamin E, and b-carotene) for
the prevention of cardiovascular events among female health
professionals aged 40 years at enrollment (mean age 60.6
years; range, 43 to 90 years), who had either preexisting CVD or
three or more coronary risk factors.(3,23,24) The sample was
approximately 94% white.(23)
Initially, the WAFACS cohort included 8171 participants who
were randomly assigned in a 2 2 2 factorial design to vitamin
C, vitamin E, b-carotene, or placebo in 1995.(23,24) Additional
funding was received to add the folic acid (2.5mg/day), vitamin
B6, (50mg/day), and vitamin B12 (1mg/day) intervention to the
study and 5442 willing participants were further randomized to
either treatment with combination B vitamins or placebo in
April 1998.(3) The design of the study is illustrated in Figure 1. The
B vitamin intervention was designed with the objective of
lowering homocysteine levels, thereby reducing the risk for CVD
in this population of high risk women. A blood substudy of a
random sample of 300 women (150 in each treatment group)
conﬁrmed that those receiving the B vitamin supplementation
had higher folate levels, and lower homocysteine levels relative
to baseline levels, and signiﬁcantly more so than the placebo
group.(3) To participate in the B vitamin intervention, women
had to forego the use of B vitamin supplements at levels greater
than the recommended dietary allowance (RDA) for the duration
of the intervention.(3)
Treatment and follow-up of the B vitamin intervention were
concluded in July 2005, with mean follow-up at study closeout
of approximately 7.3 years. As previously published, all CVD risk
factors, medication use, multivitamin use, and median intake of
the relevant nutrients (folate, B6, and B12) were very similar
between randomization arms, with no signiﬁcant differences.(3)
Fracture assessment
Throughout the treatment and follow-up period, annual follow-
up questionnaires were mailed to participants to collect self-
reported information on study outcomes including fractures
that occurred during the preceding 12-month period. Women
who reported a fracture were contacted by WAFACS staff, who
requested detailed information on each fracture reported
during the B vitamin intervention/follow-up period. Clinical
documentation to conﬁrm fractures, including medical and
radiographic reports, were requested.
The primary endpoint was conﬁrmed incident nonspine
fracture during the B vitamin intervention trial. Spine fractures
and pathological fractures were excluded. Radiographic reports
or other clinical documentation for each reported fracture were
reviewed and adjudicated centrally at the San Francisco
Coordinating Center, without knowledge of treatment assign-
ment. Women with inadequate fracture documentation were
excluded from the main analysis (n¼ 632).
Case-cohort fracture study by baseline plasma levels of
homocysteine and B vitamins
A case-cohort study designwas used to test whether the effects of
treatment on fracture risk differed among those with elevated
baseline homocysteine levels, or low levels of vitamin B6, vitamin
B12, or folate.
(25)Approximately75%ofparticipants in theBvitamin
intervention had provided EDTA plasma samples at baseline.
Following completion of the fracture adjudication, among those
with baseline plasma samples available, we selected a case-cohort
sample of 833 participants independent of active versus placebo
treatment status, which included all 274 participants with
conﬁrmed incident nonspine fractures, and a random cohort
sample of 675 participants selected regardless of fracture status.
Among the 675 women in the random cohort sample, 116 were
fracture cases, and559didnothave incident adjudicatednonspine
fracture and served as the “control” group for analyses, resulting in
an approximate control to case ratio of 2:1.
Archived blood specimens were assayed for biochemical
parameters by the Nutrition Evaluation Laboratory at the Jean
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Mayer USDA HumanNutrition Research Center on Aging at Tufts
University. Plasma total homocysteine (tHcy) was measured by
high-performance liquid chromatography using ﬂuorescence
detection (Empower HPLC System; Waters Corporation, Milford,
MA, USA).(26) The detection limit of the tHcy assay is 1 nmol/mL
and the intraassay and interassay coefﬁcients of variation (CVs)
are 4% and 7%, respectively. The reference range is 4.6 to
11.0 nmol/mL. Folate and vitamin B12 were measured by a
competitive binding protein radioimmunoassay (Quantaphase II
RIA kit; Bio-Rad Laboratories, Hercules, CA, USA). The detection
limit for the folate assay is <0.1 ng/mL and the intraassay and
interassay CVs are 3.8% to 5.2% and 4.1% to 8.7%, respectively.
The reference range is 1.5 to 20.6 ng/mL. The detection limit of
the vitamin B12 assay is 20 pg/mL and the intraassay and
interassay CVs are 4.0% to 5.9% and 4.5% to 6.8%, respectively.
The reference range is 200 to 1200 pg/mL. Pyridoxal 50-
phosphate (PLP: vitamin B6) was determined by enzymatic
radioimmunoassay using tyrosine decarboxylase apoenzyme.(27)
The detection limit of the vitamin B6 assay is 10 nmol/L and the
intraassay and interassay CVs are 5% and 9%, respectively. The
reference range is 20 to 100 nmol/L.
Markers of bone turnover
Ina separateprevious substudy,(3) a total of 300women (150 in the
active treatment and 150 in the placebo group) provided a fasting
plasma sample at randomization for the B vitamin intervention,
and at the end of randomized treatment and follow-up 7.3 years
later. C-terminal cross-linking telopeptide of type I collagen (CTX;
Roche Diagnostics, Mannheim, Germany), and marker of bone
resorption, and intact type I procollagen N-propeptide (P1NP;
Roche Diagnostics, Mannheim, Germany), a marker of bone
formation, were measured using automated platforms at a
specialized laboratory (CCBR-Synarc, Lyon, France). Intraassay and
interassay CVs are <4.4% for P1NP and <5.7% for CTX.
In this blood subgroup, the concentration of baseline total
homocysteine was previously determined by enzymatic assay
using the Hitachi 917 analyzer (Roche Diagnostics, Basel,
Switzerland). Baseline and follow-up samples were assayed in
blinded fashion in the same analytical run.(3)
Other variables
Information regarding body mass index (BMI), menopausal
status, menopausal hormone therapy (HT) use, multivitamin use,
personal use of folic acid and other B vitamin supplements,
smoking status (current, past, and never), physical activity (kcal/
day) and history of prior fracture were collected by self-reported
questionnaire at the time of the randomization in the B vitamin
intervention.(3,23)
Statistical analysis
Characteristics of the B vitamin treatment and placebo groups
were compared using t tests for continuous variables and chi-
square statistics for categorical variables.
Following intention-to-treat analysis, the effect of B vitamin
therapy versus placebo on fracture risk was assessed using Cox
proportional hazards models. The primary outcome was
adjudicated nonspine fracture. However, given that a relatively
large number (n¼ 632) had inadequate fracture documentation,
self-reported nonspine fracture was analyzed as a sensitivity
analysis. Prespeciﬁed subgroup analyses were performed
stratifying on adherence (deﬁned as those who took at least
two-thirds of their assigned pills at all follow-up time points) (Y/
N), age (65,>65 years), baseline use of B vitamin supplements
(Y/N), current smoking (Y/N), and current HT use (Y/N). Because
multivitamins often contain up to 100% of the recommended
dietary allowance for some B vitamins, we performed a
sensitivity analysis excluding those reporting use of B vitamins
or multivitamins at baseline.
Fig. 1. Randomization scheme for the Women’s Antioxidant and Folic Acid Cardiovascular Study.
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The case-cohort adaptation to the Cox proportional hazards
model was used for analysis of the effects of treatment on risk of
nonspine fracture among those with elevated baseline levels of
homocysteine (deﬁned as highest quartile), or low B6, B12, or
folate levels (deﬁned as lowest quartile). Because power for this
analysis was limited, in sensitivity analyses we also explored the
median as the cut point for these analyses.
For change in bone marker analysis, linear regression models
were used to assess effects of the treatment of interest on
percent change in untransformed P1NP and CTX, which was
calculated by 100 [(follow-up –baseline)/baseline]. Subgroup
analyses were done by HT use status, menopause status, and
baseline homocysteine level.
All analyses were conducted using SAS, version 9.4 (SAS
Institute, Inc., Cary, NC, USA).
Results
Among 5442 participants who were enrolled in the vitamin B
intervention component of WAFACS, 1229 reported incident
nonspine fractures on one or more annual questionnaires. Of
these, 632 had inadequate fracture documentation (319 in the B
vitamin group and 313 in the placebo group) andwere excluded
from analyses. An additional 248 reported fractures were
adjudicated as nonfractures. The analytic cohort was therefore
comprised of a total of 4810 women with 349 adjudicated
nonspine fractures (including 22 hip fractures, and 67 wrist
fractures). The vitamin and placebo groups were well matched
at baseline with regard to age, postmenopausal status, previous
fracture, and HT use (Table 1Table 1). Approximately two-thirds
of women reported >66% compliance with their assigned
intervention at all follow-up time points during the trial.
Fracture outcome
The risk of any nonspine fracture was similar among those
randomized to vitamin or placebo (hazard ratio [HR]¼ 1.08; 95%
conﬁdence interval [CI], 0.88 to 1.34), as were risks of hip
(HR¼ 0.99; 95% CI, 0.43 to 2.29), wrist (HR¼ 1.30; 95% CI, 0.80 to
2.11), and other fracture (HR¼ 1.03; 95% CI, 0.82 to 1.30)
(Table 2). In a sensitivity analysis, results were also similar for the
outcome of self-reported (unadjudicated) nonspine fracture
(HR¼ 1.06; 95% CI, 0.93 to 1.20) (Table 2). Results were also
unchanged by further adjustment for treatment assignment to
vitamin C, E, or beta-carotene (results not shown).
Nonspine fracture results were similar among those whowere
considered adherent to study medications during the follow-up
period, and among baseline subgroups deﬁned by age, use of B
vitamin supplements, HT use, and smoking status (all interaction
p values >0.05) (Table 3). There were similarly no signiﬁcant
effects of treatment observed after excluding those who
reported baseline use of either B vitamin supplements or
multivitamins (HR¼ 1.07; 95% CI, 0.83 to 1.36).
In the case-cohort fracture substudy, there was no evidence of
an interaction of treatment assignment with baseline plasma
levels of homocysteine, B12, or folate (Table 4). However, there
was a signiﬁcant interaction observed between baseline B6
levels and treatment (interaction p value¼ 0.04). Among those
in the lowest quartile of plasma B6 levels, there was a
nonsigniﬁcant protective effect of treatment (relative hazard
[RH]¼ 0.69; 95% CI, 0.39 to 1.22), whereas there was a signiﬁcant
increased risk observed among those with normal B6 levels
(RH¼ 1.39; 95% CI, 1.01 to 1.91). In separate sensitivity analyses,
we found no signiﬁcant interactions of treatment assignment
and baseline plasma levels of homocysteine, B12, folate, or B6
(nor did we observe any speciﬁc effects of treatment within
strata) when we stratiﬁed based on median concentrations
instead of high-risk quartile versus others.
Bone turnover markers outcome
There were no differences between treatment and placebo
groups regarding baseline and follow-up bone turnover marker
measurements and change in bonemarkers (Table 5). Change in
Table 1. Baseline Characteristics by Treatment Group Among WAFACS Women With Valid Fracture Information (n¼ 4810)
Variable Folate/vitamin B group (n¼ 2402) Placebo group (n¼ 2408) p
Age (years), mean SD 62.6 8.7 62.5 8.7 0.65
BMI, mean SD 30.5 6.6 30.6 6.7 0.55
Postmenopause status, n (%) 0.47
Yes 2193 (91.3) 2204 (91.5)
No 149 (6.2) 156 (6.5)
Unsure 60 (2.5) 48 (2.0)
Smoking status, n (%) 0.03
Never 1094 (45.6) 1035 (43.0)
Past 1046 (43.6) 1071 (44.5)
Current 262 (10.9) 302 (12.5)
Current HT use, n (%) 1245 (51.8) 1248 (51.8) 0.99
Taking multivitamin, n (%) 555 (23.1) 546 (22.7) 0.73
Taking folate/B6/B12 supplement, n (%) 184 (7.7) 166 (6.9) 0.31
Taking folate supplement 64 (2.7) 60 (2.5) 0.71
Taking B6 supplement 81 (3.4) 80 (3.3) 0.92
Taking B12 supplement 90 (3.8) 75 (3.1) 0.23
Taking other supplement with high folate/B6/B12 51 (2.1) 57 (2.4) 0.57
Prior fracture, n (%) 891 (37.1) 903 (37.5) 0.77
Physical activity (kcal per week from exercise), mean SD 1259 1779 1168 1670 0.07
Adherent to treatment, n (%)a 1600 (67.2) 1636 (68.6) 0.30
aAdherence is deﬁned as having 100% of annual follow-up questionnaires in which participant reports 67% or more study medications were taken.
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bone markers were also similar with active and placebo
treatment after stratifying for baseline HT use status (all
p> 0.3). There were similarly no signiﬁcant interactions between
treatment and menopause status or baseline homocysteine
levels.
Discussion
In this large randomized, placebo-controlled trial of women at
high risk for CVD, we found no signiﬁcant beneﬁcial or harmful
effects of daily B vitamin supplementation on nonspine fracture
risk over 7.3.years of treatment and follow-up. In a case-cohort
subsample, we similarly found no signiﬁcant effects of B
vitamins on nonspine fracture risk among those with elevated
baseline plasma homocysteine levels. Results were similarly null
in other prespeciﬁed subgroup analyses based on adherence,
age, HT use, baseline use of B vitamin supplements, and smoking
status.
Overall, our results add to the growing body of evidence from
randomized trials, demonstrating minimal effect of B vitamin
supplementation on risk of fracture.(14,15,17,28) For example, our
ﬁndings are consistent with the recently published negative
results in the B-PROOF study, in which over 2900 older adults
with elevated homocysteine levels were randomized to receive
daily B12 and folic acid supplementation or placebo for a period
of 2 years.(14) However, whereas the B-PROOF study reported a
possible protective effect among compliant individuals older
than 80 years, our prespeciﬁed subgroup analyses revealed no
signiﬁcant interaction of treatment with age or compliance to
assigned study pills. In contrast with the B-PROOF study, our
intervention was longer (7.3 years versus 2 years in B-PROOF),
and our study population comprised women at high risk of CVD,
but were not otherwise selected for high baseline homocysteine
levels. Nonetheless, our subgroup ﬁndings are consistent with
those of B-PROOF, showing no signiﬁcant effect of B vitamin
supplementation in those with elevated baseline homocysteine
levels.(14) Of the four baseline plasma biomarkers (homocyste-
ine, folic acid, B12, and B6), we observed a signiﬁcant interaction
with treatment for only one (B6), and therefore cannot rule out
chance as an explanation for this ﬁnding.
Previous results from a Japanese study by Sato and
colleagues(16) had suggested a signiﬁcant protective beneﬁt
of B vitamin supplementation on fracture risk in patients with
prior ischemic stroke; however, this study has since been
Table 2. Incident Fractures by Treatment Group During 7.3 Years of Treatment/Follow-up
Variable
Folate/vitamin B group (n¼ 2402)
n (%)
Placebo group (n¼ 2408)
n (%)
Relative hazard
(95% CI) pa
Nonspine fracture 182 (7.6) 167 (6.9) 1.08 (0.88–1.34) 0.39
Hip fracture 11 (0.5) 11 (0.5) 0.99 (0.43–2.29) 0.99
Wrist fracture 38 (1.6) 29 (1.2) 1.30 (0.80–2.11) 0.26
Other nonspine fracture 146 (6.1) 142 (5.9) 1.03 (0.82–1.30) 0.79
Self-reported (unadjudicated) nonspine
fracture
628 (23.1) 601 (22.1) 1.06 (0.93–1.20) 0.38
aValue of p from chi-square test.
Table 3. Effect of Randomized Treatment Assignment on the Primary Outcome in Prespeciﬁed Subgroups
Patients (n) Events (n)
Characteristic Active Placebo Active Placebo RR (95% CI) pa
Overall 2402 2408 182 167 1.08 (0.88–1.34)
Age 0.14
65 years 1417 1415 104 107 0.95 (0.73–1.25)
>65 years 985 993 78 60 1.32 (0.94–1.85)
Taking supplementsb 0.15
Yes 184 166 12 16 0.64 (0.30–1.35)
No 2218 2242 170 151 1.13 (0.91–1.41)
Current HRT use 0.052
Yes 1245 1248 78 88 0.87 (0.64–1.18)
No 1157 1160 104 79 1.33 (0.99–1.78)
Current smoker 0.94
Yes 262 302 13 14 1.06 (0.50–2.25)
No 2140 2106 169 153 1.08 (0.87–1.35)
Adherentc 0.62
Yes 1600 1636 129 124 1.05 (0.82–1.35)
No 782 750 53 43 1.19 (0.79–1.77)
aValue of p for interaction.
bTaking folic acid, B6, B12, and any other supplements which were above the US recommended daily allowance for folic acid, B6, and B12 at baseline
(400mg folic acid, 2mg B6, and 6mg B12).
cAdherence is deﬁned as having 100% of annual follow-up questionnaires in which participant reports 67% or more study medications were taken.
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retracted.(18) To our knowledge, there are no randomized trials
that have demonstrated signiﬁcant effects of B vitamin
supplementation for the prevention of fracture risk.
Finally, we found that a B vitamin intervention designed to
lower homocysteine levels had no differential effects on
changes in two contemporary markers of bone turnover over
7.3 years of treatment and follow-up. Results of previous trials,
typically conducted over 1-year to 2-year periods, have been
mixed,(19,20,22,29–31) with most studies conﬁrming our ﬁndings of
no signiﬁcant effects of B vitamin supplementation on changes
in bone turnover markers, despite successful lowering of plasma
homocysteine or B vitamin levels.(19,20,30) To our knowledge, the
only study to report signiﬁcant changes in bone turnover
markers was an intervention by Herrmann and colleagues,(31) in
which B vitamin supplementation was conducted in men and
women aged>54 years for a period of 1 year. In this study, both
treatment and placebo group received supplemental calcium
and vitamin D. Those in the treatment group demonstrated
signiﬁcantly decreased levels of bone alkaline phosphatase,
tartrate resistant acid phosphatase, and osteocalcin compared
to those in the placebo group. We did not examine these bone
biomarkers in our study, nor did we administer supplemental
calcium or vitamin D.
Because we did not measure BMD in our study, we were
unable to examine the effects of B vitamin supplementation on
changes in BMD, although most previous randomized trials that
have investigated this endpoint have been null.(30,32) Herrmann
and colleagues(30) reported a signiﬁcant improvement in lumbar
spine BMD after a year of supplementation with a high-dose
combination of folic acid, vitamin B6, and vitamin B12 among the
small subset (n¼ 8) with low total homocysteine concentrations
at baseline.
There is rationale for an effect of supplemental B vitamins in
fracture prevention and bone health. Prior studies demon-
strated that elevated homocysteine may interfere with collagen
cross-linking.(33,34) Collagen cross-links play an important role in
determining the stability and strength of the collagen network
so that if deﬁcient, the bone matrix could be compromised,
leading to an increased risk of fracture. Alternatively, homocys-
teine may promote oxidative damage leading to increased
fractures. For example, when homocysteine undergoes oxida-
tive metabolism to homocystine and homocysteine thiolactone,
cytotoxic reactive oxygen species, including the superoxide
anion radical and hydroxyl radical are produced, which in turn
have been shown to initiate lipid peroxidation.(35) Products of
lipid and lipoprotein oxidation have been hypothesized to be
risk factors for osteoporosis.(36) Other plausiblemechanismsmay
involve adverse effects of homocysteine on endothelial-derived
nitric oxide (eNOS), which has been shown to negatively impact
osteoblast function in mice.(37,38) There may also be direct
effects of B vitamin repletion on bone metabolism in vitamin-
insufﬁcient individuals, independently of homocysteine. With
respect to the latter possibility, it is noteworthy that approxi-
mately 30% of participants were folate deﬁcient at baseline (ie,
plasma folate<7 ng/mL), but no deﬁciency was seen at the end
of the trial in either the control or the placebo group.(3) The
Table 5. Change in Bone Turnover Markers by Treatment Group Over 7.3 Years (Pretreatment to Posttreatment)
Variable Active group Placebo group p
Baseline CTX (ng/mL) 0.21 0.14 0.23 0.15 0.17
Baseline P1NP (ng/mL) 32.3 18.2 32.7 16.3 0.85
Follow-up CTX (ng/mL) 0.28 0.20 0.28 0.19 0.93
Follow-up P1NP (ng/mL) 42.5 31.7 39.9 23.6 0.43
% Change in CTX 113.2% 251.7% 105.4% 230.9% 0.78
% Change in P1NP 67.7% 162.1% 55.7% 114.7% 0.46
Values are mean SD. Total n¼ 300, including 150 in each treatment group.
Table 4. Case-Cohort Analysis: Effect of Randomized Treatment Assignment on the Nonspine Fracture Risk by Baseline Plasma Levels of
Homocysteine, B6, and Folate
Patients (n) Events (n)
Characteristic Active Placebo Active Placebo RR (95% CI) pa
Homocysteine 0.82
High (Q4) 94 109 34 36 1.11 (0.64–1.94)
Normal (Q1–Q3) 309 321 107 97 1.20 (0.87–1.65)
Vitamin B12 0.31
Low (Q1) 109 101 37 37 0.91 (0.53–1.56)
Normal (Q2–Q4) 294 329 104 96 1.27 (0.92–1.76)
Folate 0.73
Low (Q1) 87 101 33 37 1.28 (0.74–2.22)
Normal (Q2–Q4) 316 312 108 96 1.15 (0.83–1.58)
Vitamin B6
Low (Q1) 92 110 25 38 0.69 (0.39–1.22) 0.04
Normal (Q2–Q4) 311 321 116 95 1.39 (1.01–1.91)
High homocysteine is >15.1 nmol/mL; low B12 is 334 pg/mL; low folate is 6.4 ng/mL; low B6 is 34.1 nmol/L.
aValue of p for interaction.
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improvement in the placebo group could have diminished our
ability to detect a treatment effect. Nonetheless, results from
randomized trials have largely conﬂicted with some animal
studies as well as observational studies in humans showing an
association between serum or plasma levels of homocysteine or
B vitamins and bone health.
Our study has several strengths, given that it is a large,
randomized placebo-controlled trial of B vitamin supplementa-
tion with centrally adjudicated nonspine fracture outcomes in
middle-aged to older women. The availability of pretreatment
and posttreatment markers of bone turnover is also a strength.
Compared to prior studies, the treatment and follow-up period is
relatively long at 7.3 years. Despite these major strengths, there
are also some limitations. Although power for overall fracture
effects was adequate, we had less power to examine effects of
treatment on fracture subtypes, or effects of treatment in certain
subgroups such as older women, or those with high baseline
homocysteine levels. Furthermore, we had limited power to
examine the effects of B vitamin supplementation amongwomen
who may meet criteria for deﬁciency (for example, only 1.9% of
women, 2.0% in the treatment group, and 1.9% in the placebo
group had vitamin B12 levels <200pg/mL). Although our results
are consistent with all other studies ﬁnding of no association of B
vitamin intervention with fracture risk, we cannot dismiss the
possibility that a different vitamin regimen or different dosages
may yield different results. Some studies have suggested that
relatively high doses of folic acid such as those used in our study
may increase risk of cancer. However, previous analyses in
WAFACS have found no signiﬁcant effects of treatment
assignment on risk of total invasive cancer or breast cancer.(39)
Finally, our study was restricted to middle-aged to older women
at high risk of CVD and may not be generalizable to younger
women,men, or adults at high riskof fractureorusual risk forCVD.
Because the primary outcome of the trial was CVD, we did not
collect information on family history of fracture, nor is there
informationon sunlight exposureor calcium intake. Therefore,we
were unable to determine if the treatment groupswere balanced
with respect to these fracture risk factors, and it is not possible to
rule out randomization bias with respect to such factors. Previous
intervention studies to date have been very heterogeneous with
respect to study duration, study population, fortiﬁcation status,
and dosages.(40) The possibility of a beneﬁt in terms of enhanced
bone health for certain subgroups cannot be ruled out.
In a large randomized, placebo-controlled trial, we found no
effects of long-term (7.3 year) B vitamin supplementation on risk
of nonspine fracture or markers of bone resorption in women at
high risk of CVD. Results were also null among women with
elevated baseline plasma homocysteine levels. Overall, results
from randomized trials thus far do not support a preventive
beneﬁt of supplemental B vitamins on fracture risk.
Disclosures
DK is consultant to Amgen, Inc. and Scientiﬁc Advisory Board
Member for Kalytera, Inc.
Acknowledgments
This work was supported by grant funding through the National
Institutes of Health, including the National Heart, Lung and Blood
Institute (R01 HL46959) and the National Institute of Arthritis,
Musculoskeletal and SkinDiseases (R01AR052817). Vitamin E and
its placebo were supplied by Cognis Corporation (La-Grange, IL,
USA). All other agents and their placebos were supplied by BASF
Corporation (Mount Olive, NJ, USA). Pill packaging was provided
by Cognis and BASF. We are indebted to the 5442 participants in
theWomen’s Antioxidant and Folic Acid Cardiovascular Study for
theirdedicatedandconscientious collaboration; to theentire staff
of the Women’s Antioxidant and Folic Acid Cardiovascular Study:
including Marilyn Chown, BS, MPH, Shamikhah Curry, Margarette
Haubourg, Felicia Zangi, Tony Laurinaitis, Geneva McNair,
Philomena Quinn, Harriet Samuelson, MA, Ara Sarkissian, MM,
andMartin VanDenburgh, BA; and to the following individuals for
their assistance in conducting this trial: Michelle Albert, MD, MPH,
Tobias Kurth, MD, ScD, I-Min Lee, MBBS, ScD, Aruna Pradhan, MD,
MPH, Paul Ridker, MD, MPH, and Jacqueline H. Suk, MD, MPH,
Brigham and Women’s Hospital, Boston, Massachusetts; Gavin
Blake, MBBS, Mater Misericordiae University Hospital, Dublin,
Ireland; Claudia Chae, MD, MPH, Massachusetts General Hospital,
Boston; Carlos Kase, MD, Boston University Medical Center,
Boston, Massachusetts; and James O. Taylor, MD, East Boston
Neighborhood Health Center, Boston, Massachusetts.
Authors’ roles: Study design: KS, SC, and JM. Study conduct:
KS, SC, and JM. Data collection: WC, DB, AMT, and CS.
Biochemical Assays: AMT. Data analysis: KS and LL. Data
interpretation: KS, SC, JM, LL, WC, DK, and DB. Drafting
manuscript: KS and LL. Revising manuscript content: SC, JM,
LL, DB, DK, WC, and AMT. Approving ﬁnal version of manuscript:
SC and JM. KS, LL, and SC take responsibility for the integrity of
the data analysis.
References
1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and
disability associated with osteoporotic fractures. Osteoporos Int.
2006;17(12):1726–33. DOI:10.1007/s00198-006-0172-4.
2. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine
concentrations in the third National Health and Nutrition Examina-
tion Survey (1991-1994): population reference ranges and contribu-
tion of vitamin status to high serum concentrations. Ann InternMed.
1999;131(5):331–9.
3. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B
vitamins on risk of cardiovascular events and total mortality among
women at high risk for cardiovascular disease: a randomized trial.
JAMA. 2008;299(17):2027–36. DOI:10.1001/jama.299.17.2027.
4. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Plasma
homocysteine, a risk factor for cardiovascular disease, is lowered by
physiological doses of folic acid. QJM. 1997;90(8):519–24.
5. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power shortage:
clinical trials testing the “homocysteine hypothesis” against a
background of folic acid-fortiﬁed cereal grain ﬂour. Ann Intern Med.
2001;135(2):133–7.
6. Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B. Homocysteine level and
risk of fracture: a meta-analysis and systematic review. Bone. 2012;
51(3):376–82.
7. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine
levels and the risk of osteoporotic fracture. N Engl J Med.
2004;350(20):2033–41. DOI:10.1056/NEJMoa032546.
8. Kuroda T, Tanaka S, Saito M, Shiraki Y, Shiraki M. Plasma level
of homocysteine associated with severe vertebral fracture in
postmenopausal women. Calcif Tissue Int. 2013;93(3):269–75.
DOI:10.1007/s00223-013-9754-2.
9. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive
factor for hip fracture in older persons. N Engl J Med. 2004;350-
(20):2042–9. DOI:10.1056/NEJMoa032739.
10. Nilsson K, Gustafson L, Isaksson A, Hultberg B. Plasma homocysteine
and markers of bone metabolism in psychogeriatric patients. Scand
J Clin Lab Invest. 2005;65(8):671–80.
Journal of Bone and Mineral Research EFFECTS OF B VITAMINS AND FOLATE ON FRACTURE RISK ON WOMEN 2337
11. Gerdhem P, Ivaska KK, Isaksson A, et al. Associations between
homocysteine, bone turnover, BMD, mortality, and fracture risk in
elderly women. J Bone Miner Res. 2007;22(1):127–34. DOI:10.1359/
jbmr.061003.
12. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van
Staveren WA. Homocysteine and vitamin B12 status relate to bone
turnover markers, broadband ultrasound attenuation, and fractures
in healthy elderly people. J Bone Miner Res. 2005;20(6):921–9.
DOI:10.1359/JBMR.050202.
13. Bailey RL, Looker AC, Lu Z, et al. B-vitamin status and bone mineral
density and risk of lumbar osteoporosis in older females in the
United States. Am J Clin Nutr. 2015;102(3):687–94. DOI:10.3945/
ajcn.115.108787.
14. van Wijngaarden JP, Swart KM, Enneman AW, et al. Effect of daily
vitamin B-12 and folic acid supplementation on fracture incidence in
elderly individuals with an elevated plasma homocysteine concen-
tration: B-PROOF, a randomized controlled trial. Am J Clin Nutr.
2014;100(6):1578–86. DOI:10.3945/ajcn.114.090043
15. Sawka AM, Ray JG, Yi Q, Josse RG, Lonn E. Randomized clinical trial of
homocysteine level–lowering therapy and fractures. Arch Intern
Med. 2007;167(19):2136–9. DOI:10.1001/archinte.167.19.2136.
16. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and
mecobalamin on hip fractures in patients with stroke: a randomized
controlled trial. JAMA. 2005;293(9):1082–8. DOI:10.1001/jama.293.
9.1082.
17. Gommans J, Yi Q, Eikelboom JW, Hankey GJ, Chen C, Rodgers H;
VITATOPS trial study group. The effect of homocysteine-lowering
with B-vitamins on osteoporotic fractures in patients with
cerebrovascular disease: substudy of VITATOPS, a randomised
placebo-controlled trial. BMCGeriatr. 2013;13:88. DOI:10.1186/1471-
2318-13-88.
18. Bauchner H, Fontanarosa PB. Notice of retraction: Sato Y, et al. Effect
of folate andmecobalamin on hip fractures in patients with stroke: a
randomized controlled trial. JAMA. 2005;293(9):1082–8. JAMA.
2016;315(22):2405. DOI:10.1001/jama.2016.7190.
19. Green TJ, McMahon JA, Skeaff CM,Williams SM,Whiting SJ. Lowering
homocysteine with B vitamins has no effect on biomarkers of bone
turnover in older persons: a 2-y randomized controlled trial. Am J
Clin Nutr. 2007;85(2):460–4.
20. Keser I, Ilich JZ, Vrkic N, Giljevic Z, Colic Baric I. Folic acid and vitamin
B(12) supplementation lowers plasma homocysteine but has no
effect on serum bone turnover markers in elderly women: a
randomized, double-blind, placebo-controlled trial. Nutr Res.
2013;33(3):211–9. DOI:10.1016/j.nutres.2013.01.002.
21. Salari P, Abdollahi M, Heshmat R, Meybodi HA, Razi F. Effect of folic
acid on bone metabolism: a randomized double blind clinical trial in
postmenopausal osteoporotic women. Daru. 2014;22:62. DOI:10.11
86/s40199-014-0062-9.
22. Shahab-Ferdows S, Anaya-Loyola MA, Vergara-Castaneda H, et al.
Vitamin B-12 supplementation of rural Mexican women changes
biochemical vitamin B-12 status indicators but does not affect
hematology or a bone turnovermarker. J Nutr. 2012;142(10):1881–7.
DOI:10.3945/jn.112.165712.
23. Bassuk SS, Albert CM, Cook NR, et al. The Women’s Antioxidant
Cardiovascular Study: design and baseline characteristics of
participants. J Womens Health (Larchmt). 2004;13(1):99–117.
DOI:10.1089/154099904322836519.
24. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of
vitamins C and E and beta carotene in the secondary prevention of
cardiovascular events in women: results from the Women’s
Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167-
(15):1610–8. DOI:10.1001/archinte.167.15.1610.
25. Prentice R. A case-cohort design for epidemiologic cohort studies
and disease prevention trials. Biometrika. 1986;73:1–11.
26. Araki A, Sako Y. Determination of free and total homocysteine in
human plasma by high-performance liquid chromatography with
ﬂuorescence detection. J Chromatogr. 1987;422:43–52.
27. Shin YS, Rasshofer R, Friedrich B, Endres W. Pyridoxal-50-phosphate
determination by a sensitive micromethod in human blood, urine
and tissues; its relation to cystathioninuria in neuroblastoma and
biliary atresia. Clin Chim Acta. 1983;127(1):77–85.
28. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-
loweringwith folic acid plus vitamin B12 vs placebo onmortality and
major morbidity in myocardial infarction survivors: a randomized
trial. JAMA. 2010;303(24):2486–94. DOI:10.1001/jama.2010.840.
29. Herrmann M, Stanger O, Paulweber B, Hufnagl C, Herrmann W.
Folate supplementation does not affect biochemical markers of
bone turnover. Clin Lab. 2006;52(3–4):131–6.
30. Herrmann M, Umanskaya N, Traber L, et al. The effect of B-vitamins on
biochemical bone turnover markers and bone mineral density in
osteoporotic patients: a 1-year double blind placebo controlled trial.
ClinChemLabMed. 2007;45(12):1785–92.DOI:10.1515/CCLM.2007.352.
31. Herrmann W, Kirsch SH, Kruse V, et al. One year B and D vitamins
supplementation improves metabolic bone markers. Clin Chem Lab
Med. 2013;51(3):639–47. DOI:10.1515/cclm-2012-0599.
32. Enneman AW, Swart KM, Zillikens MC, et al. The association between
plasma homocysteine levels and bone quality and bone mineral
density parameters in older persons. Bone. 2014;63:141–6.
33. Kang AH, Trelstad RL. A collagen defect in homocystinuria. J Clin
Invest. 1973;52(10):2571–8. DOI:10.1172/JCI107449.
34. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for
McKusick’s hypothesis of deﬁcient collagen cross-linking in patients
with homocystinuria. Biochim Biophys Acta. 1996;1315(3):159–62.
35. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J
Med. 1998;338(15):1042–50. DOI:10.1056/NEJM199804093381507.
36. Parhami F. Possible role of oxidized lipids in osteoporosis: could
hyperlipidemia be a risk factor? Prostaglandins Leukot Essent Fatty
Acids. 2003;68(6):373–8.
37. Aguirre J, Buttery L, O’Shaughnessy M, et al. Endothelial nitric oxide
synthase gene-deﬁcient mice demonstrate marked retardation in
postnatal bone formation, reduced bone volume, and defects in
osteoblast maturation and activity. Am J Pathol. 2001;158(1):247–57.
38. Armour KE, Armour KJ, Gallagher ME, et al. Defective bone formation
and anabolic response to exogenous estrogen inmice with targeted
disruption of endothelial nitric oxide synthase. Endocrinology.
2001;142(2):760–6. DOI:10.1210/endo.142.2.7977.
39. Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE.
Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer
risk in women: a randomized trial. JAMA. 2008;300(17):2012–21.
DOI:10.1001/jama.2008.555.
40. Bailey RL, van Wijngaarden JP. The role of B-vitamins in bone health
and disease in older adults. Curr Osteoporos Rep. 2015;13(4):256–61.
DOI:10.1007/s11914-015-0273-0.
2338 STONE ET AL. Journal of Bone and Mineral Research
